October 18, 2023
Company Description: Baiya Phytopharm Co., Ltd. (Baiya Phytopharm) commenced as a spin off in Bangkok, Thailand in 2018 to a global, clinical phase biopharmaceutical company in 2021. We specialize in plant-based biotechnology and produce recombinant molecular proteins of therapeutic value using our proprietary, transient expression technology – BaiyaPharming™. Our promising technology accelerates access to unmet medical needs and is valuable for combating various infectious diseases including epidemic and pandemic circumstances as well as cancer problem worldwide. Baiya Phytopharm is founded and led by two women, Dr. Waranyoo Phoolcharoen, PhD., with nearing two-decade expertise in plant molecular pharming and Dr. Suthira Taychakhoonavudh, PhD., with more than a decade of an experience in pharmaceutical pricing and patient access. BaiyaPharming™ technology optimizes the production of biopharmaceutical products in weeks rather than months or years, resulting in faster and lower R&D costs.
CEO/Top Company Official
Lead Product in Development
Anti-PD1; Anti-PD1 fused cytokine. Currently, our focus is on our oncology treatment assets. A plant-produced PD-1 inhibitor using PlantamabTM with mAb properties and in vitro functionality better than the reference drug. This drug candidate is expected to begin IND submission in the end of 2023, and first-in-human trial in 2024. Baiya Phytopharm is also developing new generation mAbs and cytokines via., MultiplantaTM and FuseplantaTM antibody proteins using its proprietary Baiya Pharming™ technology. These drug candidates are anticipated to prove the viability of our plant system to produce complex anti-cancer therapeutics. Improved affordability
Development Phase of Primary Product
Number Of Unlicensed Products